NeuroDerm Makes Progress On Simplified Path To Parkinson's Approval
NeuroDerm Ltd. reported Phase II results for its drug-device combination product ND0612 that reinforce its ability to fill a gap in the treatment of advanced Parkinson's disease, and it could be on the market in the US in less than three years if the company is able to stay on its revised development path.
You may also be interested in...
Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.
With several companies working on new Parkinson’s therapies to maintain therapeutic levels of levodopa, NeuroDerm thinks it has a formulation that will offer similar benefits to AbbVie’s Duopa, with less invasive therapy.
Investors took NeuroDerm on a rollercoaster ride the last two days of 2014 – first driving shares up as high as 208.5% on 30 December, only to back away from the stock on 31 December, with shares falling 26%.